OBX Obsidian Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Obsidian Therapeutics Inc reported revenue of $0, net income of −$25.9M and diluted EPS of −$1.19; for the fiscal year ended December 2025 revenue was $0.
OBX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$106M, net income −$101M (margin n/a), EPS −$7.22
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$91.3M, net income −$83.1M (margin n/a), EPS −$6.47
OBX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$25.9M, EPS −$1.19
- Quarter ended Mar 31, 2026: revenue n/a, net income −$19.6M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$26.9M, EPS −$1.93
- Quarter ended Mar 31, 2025: revenue n/a, net income −$25.0M, EPS n/a
OBX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$90.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$75.0M, share buybacks n/a
OBX balance sheet
- Jun 30, 2026: cash $18.0M, total assets $51.4M, total liabilities $21.1M, shareholders' equity −$300M
- Dec 31, 2025: cash $40.4M, total assets $88.6M, total liabilities $16.6M, shareholders' equity −$266M
- Dec 31, 2024: cash $49.8M, total assets $184M, total liabilities $20.1M, shareholders' equity −$174M
What is OBX's revenue?
Obsidian Therapeutics Inc reported $0 of revenue for the fiscal year ended December 2025.
Is OBX profitable?
No. Obsidian Therapeutics Inc lost $101M in its latest fiscal year.